Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 4

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Breast 2

Conditions

Muscular Atrophy 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × ostarine × Clear all
NCT05065411 2024-02-26

VERU-024

Veru Inc.

Phase 3 Terminated
5 enrolled
Breast

Breast Neoplasms

NCT04869943 2024-01-26

ARTEST

Veru Inc.

Phase 3 Terminated
52 enrolled
Breast

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT01355497 2020-11-09

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

GTx

Phase 3 Completed
330 enrolled 7 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Muscular Atrophy

NCT01355484 2016-03-03

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

GTx

Phase 3 Completed
321 enrolled 7 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Muscular Atrophy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡